Novartis Seeds, Inc. v. Monsanto Company ( 1999 )


Menu:
  •                        United States Court of Appeals
    FOR THE EIGHTH CIRCUIT
    _____________
    No. 99-1153MN
    _____________
    Novartis Seeds, Inc.                     *
    *
    Appellant,                  *
    * On Appeal from the United
    v.                                 * States District Court
    * for the District of
    * Minnesota.
    Monsanto Company,                        *
    *
    Appellee.                   *
    ___________
    Submitted: May 14, 1999
    Filed: September 7, 1999
    ___________
    Before RICHARD S. ARNOLD, JOHN R. GIBSON, and BOWMAN, Circuit Judges.
    ___________
    RICHARD S. ARNOLD, Circuit Judge.
    This lawsuit began in 1997 when Novartis Seeds, Inc., sued Monsanto Company
    in a Minnesota state court. The plaintiff alleged that Monsanto broke development and
    license agreements involving genetically engineered, insect-resistant seed corn. After
    removing the case to the District Court, Monsanto filed a motion to dismiss for want
    of jurisdiction over the subject matter (a Rule 12(b)(1) motion), claiming that Novartis
    Seeds lacked "standing" because assignment and transfer restrictions in the 1995
    License Agreement were violated when the plaintiff's parent company merged with
    another corporation. This breach, Monsanto argued, terminated the contract, and
    deprived Novartis of its standing to sue. The District Court agreed, holding that it did
    not have subject-matter jurisdiction. We reverse. In our view, whether an assignment
    or transfer in violation of the License Agreement took place has nothing to do with
    subject-matter jurisdiction, but rather with an arguable defense on the merits. We
    remand for further proceedings.
    I.
    The transactions at the center of this dispute are complex, and we will attempt
    to explain them simply. The plaintiff, Novartis Seeds, a company in the business of
    developing and selling seeds to farmers, was formerly known (before a name change)
    as Northrup King Company. Northrup King was a wholly owned subsidiary of the
    Sandoz Corporation, which, along with Sandoz Seeds Ltd., was a wholly owned
    subsidiary of Sandoz AG, a Swiss corporation.
    Monsanto and Sandoz Crop Protection Corporation, another Sandoz company,
    signed an agreement in 1988 that allowed Sandoz Crop and its affiliates, of which
    Northrup King was one, to use a certain kind of gene that had been developed by
    Monsanto. Use of this gene allowed Northrup King to develop commercially viable
    corn that is resistant to the European corn borer, a pest that causes millions of dollars
    in damage each year in the United States. The Development Agreement was extended
    several times, and, in 1995, was replaced by a License Agreement. The named parties
    to the License Agreement were Monsanto and Sandoz Seeds Ltd. Also parties to the
    Agreement were Sandoz Seeds' "affiliates," a group that included Northrup King.
    In late 1996, Sandoz AG merged with another Swiss corporation, Ciba-Geigy
    AG. Under Swiss law, a merger results in a new entity, and it was named Novartis
    AG. Following the merger, Sandoz Seeds Ltd. was renamed Novartis Seeds AG. In
    addition, Sandoz Corporation, which owned all of Northrup King's stock, was merged
    -2-
    into Ciba-Geigy Corporation under New York law, and Ciba-Geigy Corporation
    changed its name to Novartis Corporation. Novartis Corporation, the newly named
    parent of Northrup King, later transferred its shares in Northrup King to Novartis
    Finance Corporation, a wholly owned subsidiary of Novartis Corporation. Shortly
    thereafter, Northrup King was renamed Novartis Seeds, Inc.
    The 1995 License Agreement between Monsanto and Sandoz Seeds Ltd.
    restricted the ability of Sandoz Seeds Ltd. to transfer or assign license rights to
    Monsanto's technology. Section 10.06(a) provided that "the rights acquired
    herein . . . are not assignable or transferable in whole or in part (by operation of law or
    otherwise) to any third party without the prior written consent of Monsanto; provided,
    however, that Sandoz may assign or transfer this Agreement in whole or part as part
    of the sale or transfer of substantially all of a business to which this Agreement pertains
    to a successor or assign; provided that, advance notice is given to Monsanto and the
    successor/assignee shall enter into a written agreement with Monsanto to be bound by
    the terms, conditions and obligations of this Agreement."
    Section 10.06(a), however, was made subject to Section 10.06(b), which
    provided that "[a]ssignment or transfer under Subsection 10.06(a) to a third party
    owner or licensee of any issued or pending . . . patent right . . . which patent right
    relates to modification of insect control protein(s) from Bacillus thuringiensis (B.t.) or
    generally to the expression of one or more insect control proteins of B.t. in plants,
    including but not limited to corn, which patent right may dominate the production, use
    or sale of Licensed Corn Products by Monsanto . . . shall be void and of no effect . . .."
    Section 10.06(d) further provided that "[a]ny transfer, assignment or delegation made
    or attempted in violation of this Section 10.06 shall be void and of no effect."1
    1
    We are not sure we understand what is meant by saying, as Section 10.06(b)
    does, that one patent right "may dominate" the production, use, or sale of certain
    products. The parties have not explained this term to us. But the point is not important
    -3-
    II.
    As we have said, Novartis Seeds filed its lawsuit against Monsanto in a
    Minnesota state court, alleging (among other things) that Monsanto broke the License
    Agreement. Monsanto removed the case to the District Court and filed an answer and
    counterclaim, alleging that Novartis Seeds had itself broken the License Agreement.
    Monsanto then moved to dismiss the complaint, pursuant to Fed. R. Civ. P. 12(b)(1),
    on the grounds that Novartis Seeds lacked standing to prosecute its claims. Monsanto's
    theory, as we have described above, was that the merger between Sandoz and Ciba-
    Geigy terminated Novartis Seeds' rights under the License Agreement. Monsanto
    argued that Novartis Seeds was a third party to the Agreement and possessed no rights
    itself under the Agreement, either as a party or as a third-party beneficiary. Therefore,
    Monsanto asserted, the District Court did not have subject-matter jurisdiction to decide
    the claims. Following some discovery and a hearing, the District Court granted
    Monsanto's motion to dismiss.
    The District Court began by analyzing the corporate reorganization which had
    taken place. In the Court's view, as a result of the merger of Sandoz AG and Ciba-
    Geigy AG, "the assets and liabilities of Northrup King, a former wholly-owned
    subsidiary of Sandoz Corporation, became the assets and liabilities of Ciba-Geigy.
    Ciba-Geigy then created Novartis Seeds, Inc. . . .." Novartis Seeds, Inc. v. Monsanto
    Co., Civil No. 97-2925 (D. Minn. Dec. 4, 1998), slip op. 2. "Accordingly, all assets
    owned or held by Sandoz Seeds, Sandoz Corporation, and Northrup King became a
    part of Ciba-Geigy, the surviving company." 
    Id. at 6.
    "Because of the merger, Sandoz
    Seeds and Northrup King no longer exist. . . . The [License] Agreement and all other
    assets of Sandoz Corporation and Northrup King became Ciba-Geigy's. Ciba-Geigy
    for present purposes. Whatever "may dominate" means, whether an assignment or
    transfer in violation of the License Agreement occurred relates to a defense on the
    merits, not the existence vel non of subject-matter jurisdiction.
    -4-
    then changed its name to Novartis Corporation and branched into additional corporate
    identities such as Novartis Seeds, Inc., and Novartis Financial. The assets from Ciba-
    Geigy flowed from it to these new subsidiaries. Therefore, at the time of the merger,
    Novartis [Seeds, the plaintiff] did not even exist." 
    Id. at 7.
    In these circumstances, the Court thought, a violation of Section 10.06 had
    occurred. Whatever rights Northrup King had had under the License Agreement had
    been transferred to a new entity, which new entity, Ciba-Geigy, "was the owner of a
    pending U.S. patent right which patent right related to the expression of one or more
    insect control proteins of B.t. in plants." 
    Id. at 9.
    "[T]he transfer of assets from Sandoz
    to Ciba-Geigy violated the anti-transfer provision of the 1995 agreement. Therefore,
    Novartis Seeds, Inc. has no standing to litigate this suit against Monsanto. Thus, this
    Court lacks subject-matter jurisdiction." 
    Id. at 10.
    III.
    Under Article III, section 2 of the Constitution, our courts are limited to deciding
    actual "cases" or "controversies." That a plaintiff must have standing in order to pursue
    a lawsuit is firmly rooted in our constitutional history, and requires that a plaintiff allege
    a judicially cognizable and redressable injury. As the Supreme Court has said, "In
    essence the question of standing is whether the litigant is entitled to have the court
    decide the merits of the dispute or of particular issues." Warth v. Seldin, 
    422 U.S. 490
    ,
    498 (1975). To have standing, a plaintiff must allege an injury that is fairly traceable
    to the defendant's conduct, and the requested relief must be likely to redress the alleged
    injury.
    We have no doubt that the plaintiff here has "standing" in the constitutional,
    Article III sense. Novartis Seeds alleges that Monsanto's conduct has violated the
    License Agreement (as well as transgressed against plaintiff's legal rights in other
    respects). The requested relief would redress this alleged injury. Monsanto's answer,
    -5-
    by way of defense, is that the other side has violated the agreement in an important
    respect, by making a transfer or assignment, or an attempted transfer or assignment,
    that violates Article 10.06. Because of this breach, Monsanto argues, the plaintiff has
    no legal right to complain of any alleged breach on the part of Monsanto. As a matter
    of the English language, the word "standing" can be used to describe this sort of
    contention, but "standing" in this context is entirely distinct from "standing" for
    purposes of Article III.
    Monsanto's contention, if upheld, establishes no more than a defense on the
    merits, and the distinction between such a defense and subject-matter jurisdiction is a
    vital one. See, e.g., Bell v. Hood, 
    327 U.S. 678
    , 682 (1946), where the Supreme Court
    said:
    Jurisdiction, therefore, is not defeated as respondents
    seem to contend, by the possibility that the averments might
    fail to state a cause of action on which petitioners could
    actually recover. For it is well settled that the failure to state
    a proper cause of action calls for a judgment on the merits
    and not for a dismissal for want of jurisdiction. Whether the
    complaint states a cause of action on which relief could be
    granted is a question of law and just as issues of fact it must
    be decided after and not before the court has assumed
    jurisdiction over the controversy. If the court does later
    exercise its jurisdiction to determine that the allegations in
    the complaint do not state a ground for relief, then dismissal
    of the case would be on the merits, not for want of
    jurisdiction.
    To the same effect are Steel Co. v. Citizens for a Better Environment, 
    118 S. Ct. 1003
    ,
    1010 (1998); Campbell v. Minneapolis Public Housing Authority, 
    168 F.3d 1069
    , 1074
    -6-
    (8th Cir. 1999) ("We repeat the fundamental principle that the ultimate merits of the
    case have no bearing on the threshold question of standing.").
    If plaintiff's allegations of misconduct on the part of Monsanto have merit, and
    that is the hypothesis upon which we must proceed at this stage of the case, plaintiff
    clearly has standing in the constitutional sense. So we cannot agree with Monsanto on
    this point. Monsanto urges us, nevertheless, to affirm the judgment on the ground that
    the facts in the case are undisputed, an assignment in violation of the contract did take
    place, and that, therefore, whether the question is properly labeled as one of "standing"
    or not, judgment is appropriate in Monsanto's favor as a matter of law. We decline to
    go that far at the appellate level for a number of reasons. The matter was presented to
    the District Court as a question of subject-matter jurisdiction under Rule 12(b)(1). No
    motion to dismiss under Rule 12(b)(6) for failure to state a cause of action was ever
    ruled on, and no motion for summary judgment under Fed. R. Civ. P. 56 was ever filed.
    At the time of the District Court's ruling on the 12(b)(1) motion, discovery on the merits
    had apparently been stayed, at the request of Monsanto, for just over seven months.
    Accordingly, we are not confident that the District Court had before it, or that we have
    before us, all of the evidence that either side would consider relevant if the issue of the
    lawfulness of the assignment or transfer were presented in its proper context, that is,
    as a defense on the merits on which Monsanto, or perhaps both sides, would claim
    entitlement to judgment as a matter of law.
    In addition, although Monsanto asserts that all of the relevant facts are
    undisputed, we are not sure that this is so. Monsanto's defense goes beyond the
    assertion that the corporate reorganization resulted in an assignment or transfer contrary
    to the express words of Section 10.06. Monsanto also claims that, even if the express
    words of the contract were not violated, the corporate reorganization undertaken by the
    Sandoz companies was a violation of the covenant of good faith and fair dealing that,
    it is said, inheres in every contract. Such a contention, we think, may go beyond the
    bare historical facts, and may require inferences from those facts. We are not prepared
    -7-
    to say, on the basis of the present record, that all of those inferences would necessarily
    go one way. We are not holding that Monsanto is not entitled to judgment as a matter
    of law on such a theory. We are holding only that this question should be explored by
    the District Court on remand. We do not feel sufficiently confident to address it
    ourselves.
    So the case must go back for further proceedings on the merits. We add the
    following additional comments that may be helpful to the parties and the District Court.
    1.     The assets and liabilities of Northrup King did not, as a result of the
    corporate reorganization or otherwise, become the assets of Ciba-Geigy or of Novartis
    AG. The corporate existence of Northrup King was not affected. It continued to exist,
    and it retains title to its own assets and liabilities.
    2.      Novartis Seeds, Inc., is not a newly created corporation. It is the same
    corporation as Northrup King. What occurred was simply a name change. Novartis
    Seeds, Inc., like Northrup King, retains its separate corporate existence. It is not
    correct to say that at the time of the merger Novartis Seeds did not exist. It did exist,
    though under its former name, Northrup King.
    3.     The complaint alleges claims under the License Agreement, but it also
    alleges a number of other claims, including claims for breach of the 1988 Development
    Agreement and claims for breach of fiduciary duty. Even if a transfer occurred that
    violated the License Agreement, and even if, as a consequence, plaintiff is not entitled
    to recover for any breach of that agreement, the other claims alleged by plaintiff may
    survive. They should be separately analyzed. If, for example, some of these other
    claims accrued before the allegedly unlawful transfer, we do not see how this transfer,
    even if violative of the License Agreement, could bar them.
    -8-
    4.     Finally, about two and one-half months after plaintiff filed this action,
    Monsanto filed suit in the United States District Court for the Eastern District of
    Missouri against Novartis Seeds AG. Plaintiff claims that the allegations in this suit are
    identical to those in Monsanto's counterclaim in the present case. Plaintiff made a
    motion to enjoin Monsanto from prosecuting the Missouri lawsuit. After informal
    consultation with the judge to whom the Missouri lawsuit was assigned, the District
    Court concluded that no action on this motion was required, because the Missouri court
    had decided to stay the action before it. Then, when the District Court dismissed this
    case for lack of subject-matter jurisdiction, it denied the motion to enjoin the Missouri
    suit as moot. Plaintiff asks us to instruct the District Court to hear and decide its
    motion to enjoin.
    Plaintiff should address this request to the District Court on remand. The same
    practical reasons that led the Court not to issue an injunction, at least de facto, may still
    exist. We have no way of knowing. This is a discretionary matter best addressed by
    the District Court on remand after informing itself as to all of the relevant
    circumstances concerning the present status of both cases.
    IV.
    For the reasons given, we reverse the judgment of the District Court, which
    dismissed this case for lack of subject-matter jurisdiction. We hold that the District
    Court does have subject-matter jurisdiction. The case is remanded to that Court for
    further proceedings on the merits consistent with this opinion.
    It is so ordered.
    -9-
    A true copy.
    Attest:
    CLERK, U.S. COURT OF APPEALS, EIGHTH CIRCUIT.
    -10-